Have questions for our experts or want more information?
Contact Us Today
Webinar Overview
Off-target binding is a key challenge in biologic drug development. Choosing the right in vitro screening methods can help you reduce risk, accelerate lead selection, and support successful IND submissions. While tissue cross-reactivity (TCR) is the historical standard, cell-based protein array technology, like the Retrogenix® platform, is redefining how preclinical teams uncover and address off-target interactions as early as possible in your drug development journey.
Join us for a case-based webinar showcasing how the Retrogenix platform empowers smarter, earlier decisions across biologic formats. You’ll also learn how this platform, recently accepted into the FDA’s ISTAND Pilot Program, aligns with evolving regulatory support for NAMs and the shift toward reduced animal use.
In this webinar, you’ll discover how to:
- Harness New Approach Methodologies (NAMs) to modernize and streamline your off-target assessment strategy
- Leverage the complementary strengths of TCR and cell-based protein array technologies to enhance the weight of evidence supporting your molecule’s safety profile.
- Apply real-world case studies using cell-based protein array technologies to reduce polyspecificity risk with our featured industry guest speaker
- Confidently choose screening methods that align with your preclinical goals
Webinar Presenters
James T. Raymond, DVM, MS, DACVP, DABT
Senior Scientific Director
Charles River
Mark Aspinall-O’Dea, PhD
Associate Director
Charles River
Elizabeth S. Clark, DVM, PhD, DACVP
Senior Principal Pathologist
Boehringer Ingelheim Pharmaceuticals, Inc.